What Is Norfentanyl? The Main Fentanyl Metabolite

Norfentanyl is the inactive breakdown product the liver makes from nearly all fentanyl. It doesn’t produce a high or the other effects fentanyl does.¹ Its main importance is as evidence: a drug test that finds it shows fentanyl passed through the body. And because norfentanyl outlasts fentanyl in urine, it can still turn up after fentanyl itself has cleared, which matters when a test is used to judge recent use or abstinence.²

How the Body Turns Fentanyl Into Norfentanyl

A metabolite is a breakdown product the body makes when it processes a drug. Fentanyl’s single major metabolite in the human liver is norfentanyl.³ About 99% of fentanyl is processed this way,⁴ so almost every dose leaves norfentanyl behind.

Fentanyl works by binding tightly to the brain’s opioid receptors. Norfentanyl binds them more than 10 times less tightly.⁵ The chemical piece the liver cuts off is the part that lets fentanyl grip the receptor, so without it the compound is considered an inactive metabolite.⁶

“Inactive” has limits, though. The danger in an overdose comes from the fentanyl, not its leftover. But finding norfentanyl still means fentanyl, a dangerous drug, was taken.

Here is what happens to a dose. Whether it comes from a patch, an injection, or an illicit form that is smoked or swallowed, fentanyl reaches the blood and travels to the liver, where most of the conversion happens. The kidneys then pass norfentanyl into urine, which is why a urine sample is where most people meet the word. Norfentanyl is also easier to flush out in urine than fentanyl, which is why urine often holds more norfentanyl than fentanyl. The conversion starts right away, so for a while norfentanyl is in the body while fentanyl is still active. Over the following hours and days fentanyl falls, while norfentanyl builds up and then slowly declines.

How Long Norfentanyl Stays in Urine

In people with heavy, regular fentanyl use, urine tested positive for fentanyl about 7 days after last use on average. Norfentanyl stayed positive about 13 days on average.⁷ One person tested positive for norfentanyl for 26 days after their last use.⁸ So a negative fentanyl result alongside a positive norfentanyl result can fit use from weeks earlier.

In people with opioid use disorder, estimated urine detection windows for norfentanyl ranged from about 2.7 to 10.7 days.⁹ The time it takes to clear half the norfentanyl ranged from about 5 to 27 hours.¹⁰ In a pregnancy and postpartum treatment program, low norfentanyl levels were found long after use and should not be read alone as proof of new use.¹¹ Ask staff to look at trends, not one result, since a program shouldn’t treat a low level alone as relapse.

Fentanyl is stored in body fat and released slowly after repeated use. Heavy, daily users tend to clear it more slowly than occasional users.

For someone in treatment or on probation, the weeks after stopping often look like this: fentanyl may turn negative within about a week, while norfentanyl stays positive for a second week or longer. When results seem unfair, ask for the numbers, not just positive or negative.

One number can’t be turned into a date of last use. The reported windows are averages and ranges from specific groups, not a rule for any one person. A positive shows fentanyl was used within the window but can’t say which day or how much.

If levels drop from one test to the next, that fits a person who has stopped. If levels jump back up after falling, that usually points to new exposure rather than slow clearing, though how dilute the urine is also shifts levels, so labs often adjust for it. Comparing levels works best when the tests come from the same lab, since methods and cutoffs differ.

What a Norfentanyl Result on a Drug Test Means

Fast screening tests use antibodies that react to fentanyl’s shape. Some fentanyl screens don’t react to norfentanyl at all, and one reacted only about 3% as strongly as to fentanyl.¹² Even so, a small amount of fentanyl plus a larger amount of norfentanyl can turn that screen positive.¹³ These screens also react strongly to look-alike drugs such as acetylfentanyl and acrylfentanyl.¹⁴

Lab confirmation tests, often listed as LC-MS/MS on reports, measure fentanyl and norfentanyl separately in urine.¹⁵ Both are often present in very small amounts,¹⁶ and these tests can detect them at a few billionths of a gram per liter.¹⁷

Urine usually holds more norfentanyl than fentanyl.¹⁸ Norfentanyl with little or no fentanyl suggests use some days earlier rather than very recently. Fentanyl without norfentanyl can point to very recent use or to contamination of the sample.

A quick screening test is usually done first, either on-site with a cup or at a lab, and gives a yes-or-no answer against a set cutoff. A positive screen is preliminary: a reason to look further, not a final finding. The sample then goes for the lab confirmation test, which gives measured amounts. Only after that should a result be treated as established, so asking where your result is in this chain is a fair question.

Because some screens barely react to norfentanyl, a person whose urine holds mostly norfentanyl can get a negative screen. A negative cup doesn’t prove no fentanyl was used in the past week or two, and if there is reason to doubt it, a lab confirmation test can look for both compounds directly.

If you get a positive result you dispute, first ask whether a lab test confirmed it. Tell the reviewing doctor about any fentanyl given in surgery, the ER, or a patch, since medically prescribed fentanyl also produces norfentanyl. Then request the measured levels and compare repeat tests.

Norfentanyl is made only from fentanyl, so a confirmed result isn’t a mix-up with ordinary medicines. Everyday drugs aren’t known to turn into it, and legitimate medical fentanyl is the main innocent explanation.

Why Some People Make Norfentanyl Faster or Slower

The liver enzyme CYP3A4 is the main one turning fentanyl into norfentanyl.¹⁹ The same enzyme in the gut breaks down some fentanyl before it reaches the blood.²⁰ A related enzyme, CYP3A5, takes part too.²¹ When the enzyme is blocked, more fentanyl stays in the blood longer, so the same dose can act harder and last longer.

Other medicines can slow it down. Drugs that block this enzyme, such as the antifungal ketoconazole and the antibiotic erythromycin, cut fentanyl breakdown by 90% or more in lab tests.²² The sedative midazolam competes for the same enzyme.²³ Grapefruit and grapefruit juice also block this enzyme, with an effect that can last a day or more after drinking it. Taking these with fentanyl can leave more active fentanyl in the body, raising overdose risk.²⁴

Genes play a smaller role. In infants, those with two less-active versions of CYP3A5 cleared fentanyl about a quarter more slowly.²⁵ In fentanyl deaths, people with a weak CYP3A5 version had fentanyl processed less fully.²⁶ Very poor kidney function may also slow clearance.²⁷

If you are prescribed fentanyl, tell your prescriber about every medicine you take, including antibiotics and antifungals, and avoid grapefruit juice. Pharmacists can check a medication list against fentanyl, a simple step for anyone prescribed it. After starting a new drug, watch for extra drowsiness or slow breathing. If anyone in the home uses fentanyl, carry naloxone.

For testing, slower breakdown can mean fentanyl stays detectable longer, which helps explain why detection windows vary so much. It doesn’t create norfentanyl without fentanyl.

Norfentanyl in Hair, Blood and Newborn Testing

In overdose patients in emergency rooms, blood fentanyl was typically about two to three times norfentanyl.²⁸ Daily users had higher levels than occasional users but similar ratios.²⁹

Blood needs a needle draw and covers only a short stretch, so it is used more in hospitals and death investigations than in treatment programs. Because blood fentanyl is typically a few times higher than norfentanyl, the ratio can help judge how recently fentanyl was taken. In a clinic it is a clue, not proof, since individual metabolism shifts it.

Hair tests can find both fentanyl and norfentanyl.³⁰ Hair holds far more fentanyl than norfentanyl.³¹ Umbilical cord tissue tests detected fentanyl in about 2% of newborns screened at one lab, almost always with norfentanyl too.³² Cord testing can therefore show fentanyl exposure late in pregnancy.

Why Norfentanyl Is a Controlled Substance

Norfentanyl is also the last chemical step before fentanyl in illegal manufacturing.³³ It was easy to buy and converts to fentanyl in one reaction,³⁴ so the DEA proposed making it a Schedule II controlled substance.³⁵

A precursor is an ingredient used to make another substance, and the closer it is to the final product, the more useful it is to illicit makers. Controlling it makes it harder to buy and gives authorities a way to track suppliers. The regulation targets manufacturing, not people who test positive.

Schedule II covers drugs with accepted medical uses but high potential for misuse, with strict rules for handling and record keeping. Fentanyl is itself in this category, so placing norfentanyl there treats it as closely tied to fentanyl production. Licensed laboratories can still obtain it for testing and research under registration, which is why drug-testing labs continue to use it.

Wastewater testing also measures norfentanyl to track fentanyl use in cities.³⁶ Sewage often holds more norfentanyl than fentanyl.³⁷

1
US Pharmacist. Opioid Dosing in Renal and Hepatic Impairment ↩︎
2
PubMed Central. Protracted Renal Clearance of Fentanyl in Persons with Opioid Use Disorder ↩︎
3
Drug Metabolism and Disposition. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4 ↩︎
4
US Pharmacist. Opioid Dosing in Renal and Hepatic Impairment ↩︎
5
PubMed Central. Structure-Activity Relationships and Ligand-Dependent Arrestin Bias in μ-Opioid Receptor-Mediated ERK Activation ↩︎
6
US Pharmacist. Opioid Dosing in Renal and Hepatic Impairment ↩︎
7
PubMed Central. Protracted Renal Clearance of Fentanyl in Persons with Opioid Use Disorder ↩︎
8
PubMed Central. Protracted Renal Clearance of Fentanyl in Persons with Opioid Use Disorder ↩︎
9
PubMed Central. Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder ↩︎
10
PubMed Central. Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder ↩︎
11
PubMed Central. Prolonged detection of urine norfentanyl in individuals enrolled in a medication for opioid use disorder in pregnancy and postpartum program: a case series ↩︎
12
PubMed. Comparison of Two Commercially Available Fentanyl Screening Immunoassays for Clinical Use ↩︎
13
PubMed. Comparison of Two Commercially Available Fentanyl Screening Immunoassays for Clinical Use ↩︎
14
PubMed. Comparison of Two Commercially Available Fentanyl Screening Immunoassays for Clinical Use ↩︎
15
PubMed. Determination of fentanyl in human plasma and fentanyl and norfentanyl in human urine using LC-MS/MS ↩︎
16
PubMed. Development and validation of a sensitive ultra performance liquid chromatography tandem mass spectrometry method for the analysis of fentanyl and its major metabolite norfentanyl in urine and whole blood in forensic context ↩︎
17
PubMed Central. Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantifying Fentanyl and 22 Analogs and Metabolites in Whole Blood, Urine, and Hair ↩︎
18
Frontiers in Chemistry. Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantifying Fentanyl and 22 Analogs and Metabolites in Whole Blood, Urine, and Hair ↩︎
19
PubMed. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4 ↩︎
20
Drug Metabolism and Disposition. Fentanyl Metabolism by Human Hepatic and Intestinal Cytochrome P450 3A4: Implications for Interindividual Variability in Disposition, Efficacy, and Drug Interactions ↩︎
21
PubMed Central. Impact of CYP Enzyme Polymorphisms on Opioid Response in Anesthesia and Pain Medicine ↩︎
22
PubMed. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4 ↩︎
23
Scholars@Duke. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions ↩︎
24
PubMed. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4 ↩︎
25
PubMed Central. Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population ↩︎
26
PubMed. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases ↩︎
27
US Pharmacist. Opioid Dosing in Renal and Hepatic Impairment ↩︎
28
Clinical Toxicology. Fentanyl and norfentanyl blood concentrations among severe/life- threatening opioid overdose patients stratified by self-reported opioid use patterns ↩︎
29
Clinical Toxicology. Fentanyl and norfentanyl blood concentrations among severe/life- threatening opioid overdose patients stratified by self-reported opioid use patterns ↩︎
30
PubMed Central. Toward the Interpretation of Positive Testing for Fentanyl and Its Analogs in Real Hair Samples: Preliminary Considerations ↩︎
31
Frontiers in Chemistry. Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantifying Fentanyl and 22 Analogs and Metabolites in Whole Blood, Urine, and Hair ↩︎
32
Open Journal of Obstetrics and Gynecology. Using Umbilical Cord Tissue to Identify Prenatal Exposure to Fentanyl and Other Commonly Abused Drugs ↩︎
33
Federal Register. Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance ↩︎
34
Federal Register. Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance ↩︎
35
U.S. Drug Enforcement Administration. DEA proposes to control three precursor chemicals used to illicitly manufacture deadly fentanyl ↩︎
36
PubMed Central. Long-term tracking of opioid consumption in two United States cities using wastewater-based epidemiology approach ↩︎
37
PubMed Central. Long-term tracking of opioid consumption in two United States cities using wastewater-based epidemiology approach ↩︎